Medindia
Medindia LOGIN REGISTER
Advertisement

Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results

Saturday, September 19, 2009 General News
Advertisement


CAMBRIDGE, Mass., July 14 Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the second quarter of 2009 on Monday, July 20, 2009 after U.S. financial markets close.
Advertisement

In conjunction with the issuance of the press release, Idenix management will host a conference call at 4:30 p.m. ET on Monday, July 20, 2009 to discuss the company's financial results for the second quarter of 2009 and provide an update on the company's discovery and development programs.
Advertisement

To access the call please dial 800-774-5358 U.S./Canada or 706-758-9475 International and enter passcode 20088902 or to listen to a live webcast and view accompanying slides, go to "Calendar of Events" in the Idenix Investor Center at www.idenix.com. A replay of the call will also be available from 6:30 p.m. ET on July 20, 2009 until August 3, 2009 12:00 a.m. ET. To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 20088902. An archived webcast will also be available for two weeks after the call on the Idenix website.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus. For further information about Idenix, please refer to http://www.idenix.com.

Amy Sullivan 617-995-9838 (investors) Teri Dahlman 617-995-9905 (media)

SOURCE Idenix Pharmaceuticals, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close